1. Academic Validation
  2. Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer

Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer

  • BMC Complement Med Ther. 2023 Dec 1;23(1):433. doi: 10.1186/s12906-023-04254-8.
Yongqu Lu # 1 Kangdi Dong # 2 Meng Yang 3 Jun Liu 4
Affiliations

Affiliations

  • 1 Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.
  • 2 Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
  • 3 Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, China. mengyang7012@163.com.
  • 4 Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, China. docljun@126.com.
  • # Contributed equally.
Abstract

Background: Evodia rutaecarpa, a traditional herbal drug, is widely used as an analgesic and antiemetic. Many studies have confirmed that Evodia rutaecarpa has an Anticancer effect. Here, our study explored the bioactive ingredients in Evodia rutaecarpa acting on colorectal Cancer (CRC) by utilizing network pharmacology.

Methods: We clarified the effective ingredients and corresponding targets of Evodia rutaecarpa. CRC-related genes were obtained from several public databases to extract candidate targets. Candidate targets were used to construct a protein-protein interaction (PPI) network for screening out core targets with topological analysis, and then we selected the core targets and corresponding ingredients for molecular docking. Cell proliferation experiments and enzyme-linked immunosorbent assays (ELISAs) verified the Anticancer effect of the bioactive ingredients and the results of molecular docking.

Results: Our study obtained a total of 24 bioactive ingredients and 100 candidate targets after intersecting ingredient-related targets and CRC-related genes, and finally, 10 genes-TNF, MAPK1, TP53, Akt1, RELA, RB1, ESR1, JUN, CCND1 and MYC-were screened out as core targets. In vitro experiments suggested that rutaecarpine excelled isorhamnetin, evodiamine and quercetin in the inhibition of CRC cells and the release of TNF-α was altered with the concentrations of rutaecarpine. Molecular docking showed that rutaecarpine could effectively bind with TNF-α.

Conclusion: The pairs of ingredients-targets in Evodia rutaecarpa acted on CRC were excavated. Rutaecarpine as a bioactive ingredient of Evodia rutaecarpamight effectively inhibit the proliferation of CRC cells by suppressing TNF-α.

Keywords

Colorectal cancer; Evodia rutaecarpa; Network pharmacology; Rutaecarpine; Tumor necrosis factor.

Figures
Products